Next Article in Journal
Weight Gain in HIV Adults Receiving Antiretroviral Treatment: Current Knowledge and Future Perspectives
Next Article in Special Issue
Surgical Management of Pediatric Obstructive Sleep Apnea: Efficacy, Outcomes, and Alternatives—A Systematic Review
Previous Article in Journal
Antioxidant and Anti-Proliferative Effects of Ornithogalum balansae Extracts Collected in Black Sea Region Against Lung Cancer Cells
Previous Article in Special Issue
Preliminary Results of Developing Imaging Complexity Biomarkers for the Incidence of Severe Radiation Pneumonitis Following Radiotherapy in Non-Small Cell Lung Cancer Patients with Underlying Idiopathic Pulmonary Fibrosis
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Neurosurgical Outcomes for Intracerebral Hemorrhage in Patients Undergoing Dialysis

Department of Cerebrovascular Surgery, Saitama Medical University International Medical Center, Hidaka 350-1298, Japan
*
Author to whom correspondence should be addressed.
Life 2024, 14(11), 1366; https://doi.org/10.3390/life14111366
Submission received: 13 September 2024 / Revised: 22 October 2024 / Accepted: 22 October 2024 / Published: 24 October 2024
(This article belongs to the Special Issue Feature Papers in Medical Research: 3rd Edition)

Abstract

:
Patients on hemodialysis (HD) are at a very high risk of stroke, especially hemorrhagic stroke, with worse outcomes than the general population. We have determined the indications for urgent neurosurgery for intracerebral hemorrhage (ICH) based on the hematoma volume and neurological severity, regardless of HD status. This study aimed to evaluate the neurosurgical outcomes of ICH in patients undergoing HD. We retrospectively reviewed 38 cases of surgical removal of ICH performed in patients on HD. Patients were categorized into poor or better (0–4) and very poor (5 or 6) groups according to their modified Rankin Scale (mRS) score at discharge. Patient demographics, clinical characteristics, and operative records were retrospectively analyzed. The median Glasgow Coma Scale (GCS) score and hematoma volume were 6 and 99 mL, respectively. A total of 30 patients (78.9%) had very poor outcomes at discharge. Significant differences were observed in GCS score (13 vs. 6) and hematoma volume (53 vs. 114 mL) between the poor or better and very poor groups. The receiver operating characteristic curve analysis showed the cut-off values were 9 for GCS (AUC = 0.821) and 63.3 mL for hematoma volume (AUC = 0.812). The most common complication was rebleeding (10.5%), followed by seizures (7.9%), infection (7.9%), and cerebral edema (7.9%). In conclusion, neurosurgical outcomes of ICH in patients undergoing HD remain poor, but 21.1% of these patients achieved an mRS ≤ 4. ICH patients on HD with a GCS score > 9 or hematoma volume < 63 mL are more likely to demonstrate mRS ≤ 4 after surgical evacuation. The postoperative management of patients on HD should be performed considering specific risks, such as seizures and rebleeding.

1. Introduction

Hemodialysis (HD) is the most common form of kidney replacement therapy worldwide [1]. Access to HD has increased significantly, particularly in high-income countries [2]. Consequently, the number of patients with stroke receiving HD is also increasing [3]. Patients undergoing maintenance HD have a high incidence of intracerebral hemorrhage (ICH) and poor prognosis [4]. A previous study showed that the incidence of ICH in HD patients was higher than that of cerebral infarction (52% vs. 41%) [5]. In addition, the mortality rate from ICH is up to three times higher than from cerebral infarction, making ICH one of the leading causes of death in HD patients [6]. Several factors may contribute to the poor prognosis of patients with ICH undergoing HD, including active bleeding and hematoma expansion due to systemic anticoagulant therapy and severe cerebral edema, caused by the rapid osmolar shift due to the dialysis disequilibrium syndrome [7]. Surgical evacuation and postoperative management of ICH patients undergoing HD can be challenging due to these specific risk factors, and no guidelines have described on how to determine the indications for urgent neurosurgery in patients undergoing HD. In addition, very few reports have evaluated the neurosurgical outcomes for ICH in patients on HD [8,9].
In this study, we investigated the neurological outcomes of ICH in patients undergoing HD. We determined the indications for urgent neurosurgery for ICH based on the neurological severity and hematoma volume, regardless of HD status. We aimed to evaluate the neurosurgical outcomes and identify the risk factors for very poor outcomes in patients with ICH undergoing HD.

2. Materials and Methods

2.1. Patients and Study Design

We retrospectively reviewed the medical records of all patients (n = 38) with HD who underwent surgical removal of ICH at our institution between April 2007 and December 2023. The study protocol was reviewed and approved by Saitama Medical University International Medical Center (approval number, 2023-142). Written informed consent was waived because information from routine clinical practice was used. Patients with only intraventricular hemorrhage were excluded from the study. Patients were divided into two groups based on their clinical outcomes at discharge as follows: poor or better (0–4) and very poor (5 or 6), according to the modified Rankin Scale (mRS) [10]. These two groups were compared for the following factors: patient age, sex, medical history, oral antithrombotic medication, duration of HD, Glasgow Coma Scale (GCS) score on admission, hematoma volume, hematoma enlargement, location (putamen, thalamus, lobar region, and cerebellum), ventricular perforation, operative details (duration, blood transfusion, and complications including rebleeding), and length of hospital stay.
All ICH cases were detected using computed tomography (CT). Patients also underwent CT angiography, magnetic resonance imaging, or digital subtraction angiography to investigate the bleeding source. After these studies, neurologists and neurosurgeons discussed the indications for surgical removal according to the national stroke guidelines [11], regardless of HD status. In general, patients with small ICH (<10 mL) or ICH with minimal neurological deficit did not undergo surgery. At least one board-certified neurosurgeon was present during the surgical procedure. The hematoma was surgically removed under general anesthesia. Perioperative HD was performed according to the Japanese Society for Dialysis Therapy guidelines. HD was avoided within 24 h of ICH onset, except for severe hyperkalemia (serum K ≥ 6.0 mEq/L) or pulmonary edema. Perioperative HD was performed with reduced efficiency to minimize the effects of intracranial pressure. Hemofiltration (HF) was performed during the acute phase, and replacement fluid (Sublood BSG, Fuso, Tokyo, Japan) for HF was delivered at 20 L/session. Continuous HD was performed in patients with hemodynamic instability. Anticoagulation during dialysis was performed either with nafamostat mesylate or without anticoagulant.

2.2. Statistical Analysis

Quantitative variables are expressed as mean ± standard deviation. The x2 test or Fisher’s exact test was used to identify covariates that could be used as binary categorical dependent variables. Unpaired sample tests using Welch’s correction were used for parametric data, and Mann–Whitney U tests were used for nonparametric data. Statistical significance was set at p < 0.05. SPSS version 24 (IBM Corp., Armonk, New York, NY, USA) was used for all the statistical analyses.

3. Results

3.1. Baseline Characteristics

The baseline patient characteristics are summarized in Table 1. The median patient age was 63 (interquartile range [IQR], 56–71) years and more males (71.1%) than females (28.9%) were included. Most patients (89.5%) had hypertension, and nine (23.7%) patients had a previous stroke. Thirteen (34.2%) patients were taking oral antithrombotic medications. The median duration of dialysis was 9 (IQR, 4–15) years. Diabetic nephropathy (39.5%) was the most common HD cause, followed by chronic glomerulonephritis (18.4%), immunoglobulin A nephropathy (7.9%), polycystic kidney disease (5.3%), chronic interstitial nephritis (2.6%), and nephrosclerosis (2.6%). No significant differences in patient characteristics between the two groups were observed.

3.2. Clinical Features and Outcomes

Clinical features and outcomes are summarized in Table 2 and Figure 1. The median GCS score was 6 (IQR, 4–13). The median hematoma volume was 99 (IQR, 55–167) mL, with 15.8% of the hematomas increasing in size prior to surgical removal. The most common location of the hematoma was the putamen (57.9%), followed by the lobar region (31.6%). Ventricular perforation was observed in 76.3% of the patients. The median intraoperative blood loss was 320 (IQR, 164–444) mL and 44.7% of the patients required intraoperative blood transfusion. Approximately half of the patients experienced perioperative complications. The most complications were rebleeding (10.5%), followed by seizures (7.9%), infection (7.9%), and severe cerebral edema (7.9%). A total of 30 patients (78.9%) had a very poor outcome, including 12 patients (31.6%) who died in hospital.

3.3. Predictors of Clinical Outcomes

Significant differences were observed in the GCS score (13 vs. 6; p < 0.01) and hematoma volume (53 vs. 114 mL; p < 0.01) between the poor or better and very poor groups. Receiver operating characteristic (ROC) curve analysis showed that the cutoff values for very poor outcomes were 9 for GCS (area under the curve [AUC] = 0.821) and 63.3 mL for hematoma volume (AUC = 0.812) (shown in Figure 2). Regarding the location of the hemorrhage, putaminal hemorrhage was a predictor of very poor outcomes (25.0% vs. 66.7%; p < 0.05), while lobar hemorrhage was a predictor of poor or better outcomes (75.0% vs. 20.0%; p < 0.01). Operative time was significantly longer in the very poor group (145 vs. 214 min; p < 0.05). No rebleeding occurred within 30 days after the procedure in the poor or better group. Although no significant differences in intraoperative blood loss were observed (245 vs. 321 mL; p = 0.485), intraoperative blood transfusions tended to be more frequent in the very poor group (25.0% vs. 50.0%; p = 0.258). Perioperative complications (25.0% vs. 53.3%; p = 0.238) and length of hospital stay (24 vs. 35 days; p = 0.531) were higher in the very poor group. However, these differences were not statistically significant.

4. Discussion

Herein, we described the neurosurgical outcomes for ICH in patients undergoing HD in the current settings. We showed the cutoffs of ICH volume and GCS for very poor outcomes after surgery. Furthermore, we demonstrated the correlation between the location of the hematoma and the subsequent prognosis. A previous study demonstrated that FUNC score and intraventricular extension at admission were predictors of a very poor outcome (mRS ≥ 5) in all ICH patients on HD [12]. Although the FUNC score was not investigated in our study, the predictors identified (ICH volume, GCS, and hematoma location) constitute the primary components of the FUNC score. Conversely, the incidence of intraventricular hemorrhage resulting in intraventricular extension was not identified as a predictor of outcome in the present study. This may be due to the fact that intraventricular extension can be effectively addressed through intraoperative irrigation or drainage of the ventricle, in surgical cases.
Approximately 4 million people worldwide receive kidney replacement therapy, and HD remains the most common form. In Japan, the number of patients receiving dialysis was 349,700 by the end of 2021, with this number increasing annually [13]. Approximately 1 in 360 individuals in Japan are dependent on dialysis, making Japan the second most prevalent country in the world. Neurosurgical emergencies in patients with stroke undergoing HD are not rare. Renal dysfunction is a major risk factor for stroke and contributes significantly to stroke morbidity and mortality [3,14]. Specifically, the incidence of stroke is 8–10 times higher in patients on dialysis, and mortality has also increased [15,16]. The incidence of stroke in patients on dialysis is reported to be 10–35 per 1000 person-years, with hemorrhagic stroke accounting for 20–30% of all strokes [3,15,16]. Patients with chronic renal failure stage 3–5D, including patients on dialysis, have poor outcomes and decreased survival rates after stroke [17,18,19]. The increased risk of stroke in patients on dialysis is reported to be due to the interaction between vascular complications caused by renal dysfunction and pathological conditions specific to uremia, such as vascular calcification and the malnutrition-inflammation-atherosclerosis syndrome [3,5]. Oral anticoagulants and antiplatelet agents are cornerstones of stroke prevention. However, the hemorrhagic tendency is more pronounced in patients undergoing HD; hence, a balance between stroke prevention and bleeding risk must be considered. In addition, these patients are prone to hematoma enlargement due to anticoagulant therapy, and urgent neurosurgery is often undertaken to remove the hematoma. No guidelines or consensus exist on how to determine the indications for urgent neurosurgery in patients on dialysis with such a background because their natural history is unknown. According to the dialysis therapy guidelines for the management of cardiovascular disease, neurosurgery for ICH has a weak recommendation and low levels of evidence [20]. In Japan, the National Cerebral and Cardiovascular Center reported in the 1990s that the postoperative mortality rate of urgent neurosurgery for ICH in patients on HD was 60% and the rebleeding rate was 40%, although the sample size was small [8]. Thus, higher mortality and rebleeding rates in patients undergoing dialysis have been previously reported. In this study, the mortality rate was 31.6% and the rebleeding rate was 10.5%, indicating a decrease in mortality and rebleeding rates compared to previous studies. This may be largely due to advances in dialysis technology, anticoagulants, and their antagonists [21,22,23].
The proportion of ICH patients with very poor outcomes (mRS score: 5–6) at discharge tended to be higher in patients on dialysis (78.9% in our study) than in the general population (35.8%), as reported by the Japan Stroke Data Bank 2023 “https://strokedatabank.ncvc.go.jp/en/ (accessed on 20 October 2024)”. According to the Diagnosis Procedure Combination in Japan, the mortality rate after the surgical procedure for ICH was 7.5–17.4% in the general population [24]. Although these results are not directly comparable with those of our study, the neurosurgical outcomes of patients undergoing HD seem to be worse than those of the general population. We investigated the predictors of very poor outcomes in this context. The GCS score and hematoma volume were predictors of clinical outcomes after surgical removal of ICH. ROC analysis revealed that a GCS score of 9 and hematoma volume of 63 mL were cutoffs for predicting very poor outcomes after surgery.
Postoperative seizures and rebleeding should be considered specific complications of perioperative management. In the present study, rebleeding was the most common perioperative complication. In patients on dialysis, anticoagulant and antiplatelet drugs are often introduced due to risk factors for cardiovascular diseases, such as hypertension, hyperlipidemia, and diabetes mellitus, suggesting their involvement in the formation and growth of ICH and postoperative rebleeding [25]. β2-microglobulin-induced renal dialysis-induced amyloidosis may also contribute to the cerebrovascular vulnerability in patients on HD [26]. Maintenance dialysis has also been reported as a risk factor for postoperative seizures during neurosurgery [27]. In our study, acute seizures were the second most common perioperative complication. Although the reason for this has not been identified, this may be due to the fact that electrolyte imbalance and hypotension easily occur in patients undergoing dialysis because of the rapid clearance from the blood compared to the cerebrospinal fluid, uremia, and metabolic disorders associated with end-stage renal failure, as well as additional surgical invasiveness [28]. Therefore, the prophylactic administration of anticonvulsants before and after urgent neurosurgery in patients on HD may be useful for improving outcomes. However, the timing and blood concentration of anticonvulsants, such as levetiracetam and lacosamide, which have been widely used in recent years, should be carefully monitored because of their high clearance by dialysis [29].

Limitations

This study has several limitations. First, this was a single-center retrospective non-randomized study with a limited number of patients. Second, direct comparison between the non-dialysis and non-surgical patients was lacking, making statistical investigation difficult. Third, neurosurgeons were not standardized, and outcomes may have been influenced by their individual learning curves, although at least one board-certified neurosurgeon was present throughout the surgical procedure to ensure the quality of the surgery. Therefore, concluding the efficacy and safety of the surgical removal of ICH in patients on HD, based solely on the results of this study, is challenging. Nevertheless, we believe that this study will help neurosurgeons consider the indications for surgical removal of ICH in patients undergoing HD. Further studies are needed, including prospective studies and comparisons with non-dialysis patients.

5. Conclusions

Although the neurological outcomes of ICH in patients on HD remain poor, 21.1% of these patients achieved an mRS ≤ 4 after surgical evacuation. Based on our results, ICH patients on HD with a GCS score > 9 or hematoma volume < 63 mL are more likely to demonstrate mRS ≤ 4 after surgical evacuation. Postoperative management of HD patients should consider specific risks, such as seizures and rebleeding.

Author Contributions

Conceptualization, T.M., M.M. and H.K.; Methodology, T.M. and H.K.; Software, T.M.; Investigation, M.M. and N.N.; Writing—Original Draft Preparation, T.M., M.M.; Writing—Review and Editing, K.O., Y.T., A.S., K.S., H.O. and H.K.; Supervision, H.K.; Project Administration, H.K. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of the Saitama Medical University International Medical Center (approval number, 2023-142).

Informed Consent Statement

The requirement for written informed consent was waived due to the retrospective design of the study. Patients in the study were given the opportunity to refuse to participate in the study by opting out.

Data Availability Statement

The data presented in this study are available on request from the corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Bello, A.K.; Levin, A.; Tonelli, M.; Okpechi, I.G.; Feehally, J.; Harris, D.; Jindal, K.; Salako, B.L.; Rateb, A.; Osman, M.A.; et al. Assessment of global kidney health care status. JAMA 2017, 317, 1864–1881. [Google Scholar] [CrossRef] [PubMed]
  2. Bello, A.K.; Okpechi, I.G.; Osman, M.A.; Cho, Y.; Htay, H.; Jha, V.; Wainstein, M.; Johnson, D.W. Epidemiology of haemodialysis outcomes. Nat. Rev. Nephrol. 2022, 18, 378–395. [Google Scholar] [CrossRef] [PubMed]
  3. Power, A. Stroke in dialysis and chronic kidney disease. Blood Purif. 2013, 36, 179–183. [Google Scholar] [CrossRef] [PubMed]
  4. Seliger, S.L.; Gillen, D.L.; Longstreth, W.T., Jr.; Kestenbaum, B.; Stehman-Breen, C.O. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int. 2003, 64, 603–609. [Google Scholar] [CrossRef] [PubMed]
  5. Toyoda, K.; Fujii, K.; Fujimi, S.; Kumai, Y.; Tsuchimochi, H.; Ibayashi, S.; Iida, M. Stroke in patients on maintenance hemodialysis: A 22-year single-center study. Am. J. Kidney Dis. 2005, 45, 1058–1066. [Google Scholar] [CrossRef]
  6. Sakamoto, N.; Ishikawa, E.; Aoki, K.; Uemae, Y.; Komatsu, Y.; Matsumura, A. Clinical outcomes of intracerebral hemorrhage in hemodialysis patients. World Neurosurg. 2014, 81, 538–542. [Google Scholar] [CrossRef]
  7. Murakami, M.; Hamasaki, T.; Kimura, S.; Maruyama, D.; Kakita, K. Clinical features and management of intracranial hemorrhage in patients undergoing maintenance dialysis therapy. Neurol. Med. Chir. 2004, 44, 225–232. [Google Scholar] [CrossRef]
  8. Suzuki, S.; Hashimoto, N.; Kimura, G.-J. Neurosurgical procedures in hemodialytic patients-analysis of 26 cases of intracranial hemorrhagic diseases and review of literature on cerebral aneurysms with renal failure. Surg. Cereb. Stroke 1996, 24, 193–198. [Google Scholar] [CrossRef]
  9. Gondo, G.; Fujitsu, K.; Kuwabara, T.; Mochimatsu, Y.; Ishiwata, Y.; Oda, H.; Takagi, N.; Yamashita, T.; Fujino, H.; Kim, I.; et al. Comparison of Five Modes of Dialysis in Neurosurgical Patients with Renal Failure. Neurol. Med. Chir. 1989, 29, 1125–1131. [Google Scholar] [CrossRef]
  10. Saver, J.L.; Chaisinanunkul, N.; Campbell, B.C.V.; Grotta, J.C.; Hill, M.D.; Khatri, P.; Landen, J.; Lansberg, M.G.; Venkatasubramanian, C.; Albers, G.W.; et al. Standardized Nomenclature for Modified Rankin Scale Global Disability Outcomes: Consensus Recommendations From Stroke Therapy Academic Industry Roundtable XI. Stroke 2021, 52, 3054–3062. [Google Scholar] [CrossRef]
  11. Miyamoto, S.; Ogasawara, K.; Kuroda, S.; Itabashi, R.; Toyoda, K.; Itoh, Y.; Iguchi, Y.; Shiokawa, Y.; Takagi, Y.; Ohtsuki, T.; et al. Japan Stroke Society Guideline 2021 for the Treatment of Stroke. Int. J. Stroke 2022, 17, 1039–1049. [Google Scholar] [CrossRef] [PubMed]
  12. Watanabe, Y.; Suzuki, K.; Inoue, T.; Kurita, H.; Okada, H. Functional prognosis following spontaneous intracerebral hemorrhage in patients on hemodialysis: A retrospective study of 100 consecutive cases. Ren. Replace. Ther. 2024, 10, 12. [Google Scholar] [CrossRef]
  13. Hanafusa, N.; Abe, M.; Joki, N.; Hoshino, J.; Wada, A.; Kikuchi, K.; Goto, S. 2021 Annual Dialysis Data Report, JSDT Renal Data Registry. Jpn. Soc. Dial. Ther. 2022, 55, 665–723. [Google Scholar] [CrossRef]
  14. Naganuma, T.; Takemoto, Y. New aspects of cerebrovascular diseases in dialysis patients. Contrib. Nephrol. 2015, 185, 138–146. [Google Scholar] [CrossRef] [PubMed]
  15. Foley, R.N.; Gilbertson, D.T.; Murray, T.; Collins, A.J. Long interdialytic interval and mortality among patients receiving hemodialysis. N. Engl. J. Med. 2011, 365, 1099–1107. [Google Scholar] [CrossRef] [PubMed]
  16. Power, A.; Chan, K.; Singh, S.K.; Taube, D.; Duncan, N. Appraising stroke risk in maintenance hemodialysis patients: A large single-center cohort study. Am. J. Kidney Dis. 2012, 59, 249–257. [Google Scholar] [CrossRef]
  17. Lee, J.G.; Lee, K.B.; Jang, I.M.; Roh, H.; Ahn, M.Y.; Woo, H.Y.; Hwang, H.W. Low glomerular filtration rate increases hemorrhagic transformation in acute ischemic stroke. Cerebrovasc. Dis. 2013, 35, 53–59. [Google Scholar] [CrossRef]
  18. Molshatzki, N.; Orion, D.; Tsabari, R.; Schwammenthal, Y.; Merzeliak, O.; Toashi, M.; Tanne, D. Chronic kidney disease in patients with acute intracerebral hemorrhage: Association with large hematoma volume and poor outcome. Cerebrovasc. Dis. 2011, 31, 271–277. [Google Scholar] [CrossRef]
  19. Ovbiagele, B.; Sanossian, N.; Liebeskind, D.S.; Kim, D.; Ali, L.K.; Pineda, S.; Saver, J.L. Indices of kidney dysfunction and discharge outcomes in hospitalized stroke patients without known renal disease. Cerebrovasc. Dis. 2009, 28, 582–588. [Google Scholar] [CrossRef]
  20. Hirakata, H.; Nitta, K.; Inaba, M.; Shoji, T.; Fujii, H.; Kobayashi, S.; Tabei, K.; Joki, N.; Hase, H.; Nishimura, M.; et al. Japanese Society for Dialysis Therapy guidelines for management of cardiovascular diseases in patients on chronic hemodialysis. Ther. Apher. Dial. 2012, 16, 387–435. [Google Scholar] [CrossRef]
  21. Chen, A.; Stecker, E.; Bruce, A.W. Direct oral anticoagulant use: A practical guide to common clinical challenges. J. Am. Heart Assoc. 2020, 9, e017559. [Google Scholar] [CrossRef] [PubMed]
  22. De Caterina, R.; Ageno, W.; Agnelli, G.; Chan, N.C.; Diener, H.C.; Hylek, E.; Raskob, G.E.; Siegal, D.M.; Verheugt, F.W.A.; Lip, G.Y.H.; et al. The non-vitamin K antagonist oral anticoagulants in heart disease: Section V-Special Situations. Thromb. Haemost. 2019, 119, 14–38. [Google Scholar] [CrossRef] [PubMed]
  23. Ayman, K. Advances in Hemodialysis Techniques. In Hemodialysis; Hiromichi, S., Ed.; IntechOpen: Rijeka, Croatia, 2013; Chapter 20. [Google Scholar] [CrossRef]
  24. Suga, S.; Koike, K.; Inoue, S.; Katayama, M. The current state of non-traumatic intracranial hemorrhage treatment in Japan using the diagnosis procedure combination data from 2014. Surg. Cereb. Stroke 2018, 46, 348–353. [Google Scholar] [CrossRef]
  25. Holden, R.M.; Harman, G.J.; Wang, M.; Holland, D.; Day, A.G. Major bleeding in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2008, 3, 105–110. [Google Scholar] [CrossRef] [PubMed]
  26. Gejyo, F.; Narita, I. Current clinical and pathogenetic understanding of beta2-m amyloidosis in long-term haemodialysis patients. Nephrology 2003, 8, S45–S49. [Google Scholar] [CrossRef]
  27. Fushihara, G.; Kamide, T.; Kimura, T.; Takeda, R.; Ikeda, T.; Kikkawa, Y.; Araki, R.; Kurita, H. Factors associated with early seizures after surgery of unruptured intracranial aneurysms. Clin. Neurol. Neurosurg. 2019, 178, 93–96. [Google Scholar] [CrossRef]
  28. Jabbari, B.; Vaziri, N.D. The nature, consequences, and management of neurological disorders in chronic kidney disease. Hemodial. Int. 2018, 22, 150–160. [Google Scholar] [CrossRef]
  29. Asconapé, J.J. Use of antiepileptic drugs in hepatic and renal disease. Handb. Clin. Neurol. 2014, 119, 417–432. [Google Scholar] [CrossRef]
Figure 1. Modified Rankin Scale (mRS) score at discharge.
Figure 1. Modified Rankin Scale (mRS) score at discharge.
Life 14 01366 g001
Figure 2. Receiver operating characteristic (ROC) curve for predicting very poor outcomes based on the Glasgow Coma Scale (GCS, (A)) and hematoma volume (B). The area under the curve was 0.821 and 0.812 for GCS and hematoma volume, respectively.
Figure 2. Receiver operating characteristic (ROC) curve for predicting very poor outcomes based on the Glasgow Coma Scale (GCS, (A)) and hematoma volume (B). The area under the curve was 0.821 and 0.812 for GCS and hematoma volume, respectively.
Life 14 01366 g002
Table 1. Baseline characteristics of all 38 patients with intracerebral hemorrhage on dialysis.
Table 1. Baseline characteristics of all 38 patients with intracerebral hemorrhage on dialysis.
AllPoor or BetterVery Poorp Value
No. of patients38 (100)8 (21.1)30 (78.9)
Age (yrs), median [IQR]63 [56–71]60 [53–64]64 [56–71]0.390
Female sex11 (28.9)3 (37.5)8 (26.7)0.667
Past medical history
 Hypertension34 (89.5)8 (100)26 (86.7)0.560
 Diabetes15 (39.5)3 (37.5)12 (40.0)1.000
 Hyperlipidemia3 (7.9)1 (12.5)2 (6.7)0.519
 Any stroke9 (23.7)1 (12.5)8 (26.7)0.650
Oral antithrombotic medication13 (34.2)1 (12.5)12 (40.0)0.222
 Antiplatelets11 (28.9)1 (12.5)10 (33.3)0.395
 Anticoagulants3 (7.9)1 (12.5)2 (6.7)0.519
Basic disease for dialysis
 Chronic glomerulonephritis7 (18.4)0 (0)7 (23.3)0.307
 Chronic interstitial nephritis1 (2.6)1 (12.5)0 (0)0.211
 Diabetic nephropathy15 (39.5)3 (37.5)12 (40.0)1.000
 IgA nephropathy3 (7.9)1 (12.5)2 (6.7)0.519
 Nephrosclerosis1 (2.6)0 (0)1 (3.3)1.000
 Polycystic kidney disease2 (5.3)0 (0)2 (6.7)1.000
 Others9 (23.7)3 (37.5)6 (20.0)0.363
Duration of dialysis (yrs), median [IQR]9 [4–15]8 [6–16]9.0 [4–14]1.000
Values are number (%) except where indicated otherwise. IQR, interquartile range.
Table 2. Clinical features and outcomes of patients with intracerebral hemorrhage on dialysis.
Table 2. Clinical features and outcomes of patients with intracerebral hemorrhage on dialysis.
AllPoor or BetterVery Poorp Value
Glasgow Coma Scale, median [IQR]6 [4–13]13 [10–14]6 [3–8]0.006
Hematoma volume (mL), median [IQR]99 [55–167]53 [50–65]114 [79–170]0.008
Hematoma enlargement6 (15.8)4 (50.0)2 (6.7)0.012
Location
 Putamen22 (57.9)2 (25.0)20 (66.7)0.049
 Thalamus3 (7.9)0 (0)3 (10.0)1.000
 Lobar12 (31.6)6 (75.0)6 (20.0)0.007
 Cerebellum2 (5.3)0 (0)2 (6.7)1.000
Venticular perforation29 (76.3)5 (62.5)24 (80.0)0.363
Operative time (min), median [IQR]200 [163–259]145 [98–189]214 [176–269]0.012
Intraoperative blood loss (mL), median [IQR]320 [164–444]245 [98–420]321 [166–442]0.485
Intraoperative blood transfusion17 (44.7)2 (25.0)15 (50.0)0.258
Perioperative complication18 (47.4)2 (25.0)16 (53.3)0.238
 Rebleeding *4 (10.5)0 (0)4 (13.3)0.560
 Seizure3 (7.9)1 (12.5)2 (6.7)0.519
 Infection3 (7.9)1 (12.5)2 (6.7)0.519
 Severe cerebral edema3 (7.9)0 (0)3 (10.0)1.000
Hospital stay (day), median [IQR]28 [12–48]24 [23–28]35 [9–65]0.531
* Rebleeding within 30 days after the procedure. Values are number (%) except where indicated otherwise. IQR, interquartile range.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Maeda, T.; Miyata, M.; Naito, N.; Onodera, K.; Take, Y.; Shibata, A.; Suzuki, K.; Ooigawa, H.; Kurita, H. Neurosurgical Outcomes for Intracerebral Hemorrhage in Patients Undergoing Dialysis. Life 2024, 14, 1366. https://doi.org/10.3390/life14111366

AMA Style

Maeda T, Miyata M, Naito N, Onodera K, Take Y, Shibata A, Suzuki K, Ooigawa H, Kurita H. Neurosurgical Outcomes for Intracerebral Hemorrhage in Patients Undergoing Dialysis. Life. 2024; 14(11):1366. https://doi.org/10.3390/life14111366

Chicago/Turabian Style

Maeda, Takuma, Mayuko Miyata, Nobuaki Naito, Koki Onodera, Yushiro Take, Aoto Shibata, Kaima Suzuki, Hidetoshi Ooigawa, and Hiroki Kurita. 2024. "Neurosurgical Outcomes for Intracerebral Hemorrhage in Patients Undergoing Dialysis" Life 14, no. 11: 1366. https://doi.org/10.3390/life14111366

APA Style

Maeda, T., Miyata, M., Naito, N., Onodera, K., Take, Y., Shibata, A., Suzuki, K., Ooigawa, H., & Kurita, H. (2024). Neurosurgical Outcomes for Intracerebral Hemorrhage in Patients Undergoing Dialysis. Life, 14(11), 1366. https://doi.org/10.3390/life14111366

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop